R.A. Session II - Nov 23, 2021 Form 4 Insider Report for Taysha Gene Therapies, Inc. (TSHA)

Role
President and CEO, Director, 10%+ Owner
Signature
/s/ Kamran Alam, Attorney-in-Fact
Stock symbol
TSHA
Transactions as of
Nov 23, 2021
Transactions value $
$529,102
Form type
4
Date filed
12/8/2021, 03:05 PM
Next filing
Feb 25, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TSHA Common Stock Purchase $200K +16.5K +0.18% $12.12* 9.16M Nov 23, 2021 Direct F1
transaction TSHA Common Stock Purchase $329K +26K +0.28% $12.65* 9.19M Nov 23, 2021 Direct F2
holding TSHA Common Stock 141K Nov 23, 2021 See footnote F3
holding TSHA Common Stock 141K Nov 23, 2021 See footnote F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.46 to $12.45 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (1) and (2).
F2 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.46 to $12.94 inclusive.
F3 The securities are held by RA Session II, as Trustee of the Session 2020 Annuity Trust I.
F4 The securities are held by RA Session II, as Trustee of the Session 2020 Annuity Trust II.